Clinical trial
Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
NCT00005800 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00005800 |
|---|---|
| Title | Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer |
| Official title | A Phase II Neoadjuvant Trial of Sequential Doxorubicin and Docetaxel for the Treatment of Stage III Breast Cancer Measuring STAT Activation as a Predictor of Response to Therapy |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | Filgrastim, Docetaxel, Doxorubicin, Surgery |
| Enrollment | 45 |
| Start date | Apr 1, 1999 |
| Primary completion | Jan 1, 2006 |
| Completion | May 1, 2012 |
| First posted | Oct 8, 2003 |
| Last update posted | Sep 25, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: